Biotech /Tiergesundheit

Der Bereich Tiergesundheit wird in aller Regel von kleinen Tochterfirmen der großen Pharmakonzerne abgedeckt. Wirkstoffe sind in den meinsten Fällen aus dem Humanbereich.

Das Betätigungsfeld ist attraktiv und Wachstumsstark. Aratana erwirbt Rechte für Substanzen die bereits in der Humanmedizin zugelassen sind. Diese werden dann auf ihre Wirksamkeit in der Tiergesundheit getestet.
Die Umsätze sind noch gering, es werden Verluste gemacht aber das sollte sich bereits im kommenden Jahr drehen.
Aktuell sind zwei Medikamente zugelassen. Es gibt eine Partnerschaft mit Elanco Animal Health Division of Eli Lilly. Für diese Parnterschaft gibt es in Q2 ein Upfrontpayment von 45Mio USD dazu kommen Meilensteinzahlungen. Dafür hat Aratana die weltweiten Rechte EX US and Elanco abgetreten. Für den US Markt gibt es Covermarktungsrechte.
Die Vereinbarung betrifft das Medikament grapiprant. Daneben gibt es bereits die Zulassung für ein weiteres Medikament.

Das Marktpotential:

The biotech landscape is full of companies tackling diseases and medical issues that plague humans. Aratana Therapeutics is taking a different approach to the pharmaceutical market by developing products to treat animals. U.S. pet owners spent nearly $60 billion on their animal companions in 2014, and that number will only rise as effective pet therapeutics hit the market. The market for veterinary medicine is less crowded obviously than that for humans. 45 new drug applications (NDAs) were filed with the FDA for new drugs for humans in 2015, and only five for animals.

Das Geschäftsmodell und Link zur Homepage:
http://www.aratana.com/about/business-model/

 

 

Pet therapeutics firm Aratana Therapeutics has named Brent Standridge to the newly created post of chief operating officer.

Most recently, Standridge was consulting for generic veterinary drugmaker Putney (recently acquired by Dechra Pharmaceuticals), and he spent 28 years before that with Fort Dodge Animal Health, the animal health division of Wyeth.

 

They say good things come in threes, which is true for Aratana Therapeutics Inc.

The Leawood-based animal health company has filed an administrative New Animal Drug Application with the Food and Drug Administration's Center for Veterinary Medicine for the drug Nocita.

In just the past few months, the company received FDA approvals for the drugs Galliprant and Entyce. Galliprant, which aims to help control the pain and inflammation in dogs with osteoarthritis, received approval in March. Entyce, a flavored, oral liquid prescription that helps stimulate appetite in dogs, received its approval in May.

That's on top of a deal with a big-name animal health company, Elanco, Eli Lilly and Co.'s animal health division, based in Greenfield, Ind. Aratanagranted licensing rights to Elanco to develop, manufacture, market and commercialize Galliprant globally. Aratana will receive an upfront payment of $45 million; additional payments up to $83 million upon achievement of certain development, regulatory and sales milestones; and co-promotion fees and royalty payments, according to an 8-K filing with the Securities and Exchange Commission.

http://www.bizjournals.com/kansascity/news/2016/06/30/aratana-therapeutics-fda-approval-nocita.html?ana=yahoo&yptr=yahoo

 

A Growing Player Within The Emerging Pet Therapeutics Market
Over the last several decades, the animal health market has outgrown the U.S. economy and been more resistant to economic cycles. Moreover, the vet market is an attractive vehicle for investors to participate in the growth of the broader healthcare industry without reimbursement risk. U.S. consumers will spend an estimated $55.53 billion on pets this year - a number that has been growing at a pace of more than 5% over the past decade. Therapeutics constitutes a small portion of this market but is poised to expand as pet care becomes more complex and companies roll out new products for unmet needs. In this article, we decided to evaluate Aratana Therapeutics (PETX), a small-cap biopharmaceutical company developing...

Quelle:

​

 

Veterinary drug concern Aratana Therapeutics (NASDAQ:PETX) received a Buy rating and $15 price target from Lake Street on Friday. The analyst firm sees Aratana "being able to emerge as a leading innovator in the companion animal veterinary medicines market". The company should have three if not four successful NDAs this year. 

http://www.benzinga.com/analyst-ratings/analyst-color/16/07/8222453/weakness-in-aratana-shares-an-excellent-entry-point

 

Erklärung: Im Vorposting steckt hier  Aratana Therapeutics (NASDAQ:PETX) received  ( genau im Wort received) der Link)

Wahrscheinlich kommt es ohnehin durch Moderatoren die der englischen Sprache nur bedingt mächtig sind zu Löschungen.

In diesem Sinne wünsche ich einen charmanten Abend.

 

werden am Freitag den 5ten August veröffentlicht.

Aratana hat sich in den letzten Wochen gute entwickelt. Das Potential ist enorm, die Marktkapitalisierung nach wie vor sehr gering.

Eine spannende Story.

narbonne  

Aratana Therapeutics (NASDAQ:PETX): Q2 EPS of $0.61 beats by $0.37.

Revenue of $38.05M beats by $30.44M.

Press Release

Enthalten ist eine Einmalzahlung die allerdings zuvor bekannt war. Unglaublich starke Zahlen. Langfristig ist Aratana ein Kauf und vielleicht eines der besten Investments. Kurzfristig ist der Kurs schon sehr weit gelaufen. Nach Börsenschluss in den USA kam es noch zu einem Sprung auf 8,50 USD.

Ich werde weiter zukaufen.

narbonne

 

The FDA's Center for Veterinary Medicine approves Aratana Therapeutics' (NASDAQ:PETX) NOCITA (bupivacaine liposome injectable suspension) for local post-operative analgesia in dogs following cranial cruciate ligament surgery.NOCITA is a local anesthetic that lasts up to 72 hours after surgery by slowly releasing bupivacaine over time. It is administered in a single dose by tissue infiltration during wound closure.

Der Aktienkurs ist nach Handelsschluss um 5% gestiegen. 

 

https://www.finanzen.net/analyse/...-Stifel_Nicolaus__Co__Inc__639859  

https://seekingalpha.com/news/...atana-27-percent-stifel-softens-view  

https://www.marketwatch.com/story/...erapeutics-2019-04-26?siteid=rss

https://m.nasdaq.com/de/symbol/petx/real-time